<DOC>
	<DOCNO>NCT00120796</DOCNO>
	<brief_summary>Chronic hepatitis B infection major public health issue Senegal . The study compare efficacy treatment strategy combine Lamivudine therapeutic vaccine ( 12 intra-muscular injection 6-month period ) treatment Lamivudine alone control viral replication patient replicative hepatitis B virus ( HBV ) infection increase hepatic enzyme .</brief_summary>
	<brief_title>Lamivudine Therapeutic Vaccine Evaluation Senegalese Patients With Chronic Hepatitis B Infection ( ANRS 12100 HEPADAK-2 )</brief_title>
	<detailed_description>Hepatitis B infection prevalence high 15 % positive Ag HBs subject major public health issue Senegal . A program treatment patient present hepatic disease currently ongoing network specialist GI tract liver disease . Hepatitis B real threat Senegalese population show pilot study ( HEPADAK I ) perform Dakar Hospital Principal ( DHP ) Dakar among 100 blood donor 50 patient liver disease . This study allow u good characterize strain molecular level . The aim project assess pragmatic treatment strategy apply Senegal develop country patient require treatment . A recent Japanese study perform Ag HBe positive patient report interest combination Lamivudine ( LAM ) therapeutic vaccine negativation viral load 100 % patient one year treatment . It important show treatment 12 intra-muscular injection vaccine 6-month period feasible Africa ass result treatment Senegalese population , mainly AgHBe negative . The study HEPADAK 2 randomize open label study compare efficacy treatment strategy combine Lamivudine therapeutic vaccine ( 12 intra-muscular injection Engerix B 6-month period ) treatment Lamivudine alone control viral replication patient replicative HBV infection increase transaminase . Eligible patient HIV , HDV HCV negative ) give write informed consent ; ii ) B hepatitis grade equal F2 Metavir score , DNA HBV great 105 copies/mL ( 104 copies/mL Ag Hbe - ) , ALAT great 1.3 time upper limit normal ; iii ) accept liver biopsy follow protocol DHP . After 3-month treatment Lamivudine , patient whose viral load negative least decrease 4 Log randomize treatment 9-month period treatment combine 12 injection vaccine 6 month . The main endpoint undetectability HBV DNA blood level 12 month treatment initiation 6 month end treatment . Secondary endpoint HBV DNA blood level 3 , 6 , 9 12 month end treatment , transaminases blood level , Lamivudine treatment compliance , feasibility vaccine injection schedule , safety , AgHBe seroconversion ( positive patient ) negativation AgHBs . Two hundred ten patient include ( 70 Lamivudine group , 140 Lamivudine + vaccine group ) order show difference least 20 % percentage patient undetectable viral load 12 month ( 70 % expect Lamivudine monotherapy ) , power 90 % , alpha risk equal 5 % bilateral test . Patients virological failure maintain retreated Lamivudine . For patient YMDD mutation , treatment Adefovir Dipivoxil possible . Patients ' inclusion plan start January 2005 end 12 18 month . Patients treat one year follow one year without treatment study protocol , manage necessary</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Written inform consent Liver biopsy acceptation B hepatitis grade equal F2 Metavir score DNA HBV great 100000 copies/mL ( 10000 copies/mL Ag Hbe negative ) ALAT great 1.3 time upper normal limit HCV , HDV HIV positive Pregnancy Decompensated liver cirrhosis Pretreated patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Hepatitis B Vaccines</keyword>
	<keyword>Lamivudine</keyword>
</DOC>